Trial Profile
Desensitization of highly pre-sensitized dialysis patients waiting for kidney transplantation by rituximab, intravenous immunoglobulin-L (IVIG-L) and rescue plasmapheresis (AMC-DRIP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2013
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary) ; Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms DRIP
- 29 Jun 2013 Status changed from planning to completed as reported by ISRCTN: Current Controlled Trials.
- 25 Jun 2007 New trial record.